James Crowley: Study suggests that GLP-1RAs are associated with reduced risk of several hematologic cancers
James Crowley, Professor of Medicine Emeritus at Brown University, shared a post on LinkedIn about a paper by Omer Ashruf et al. published in JAMA Network Open:
“The findings of this cohort study suggest that GLP-1RAs are associated with reduced risk of developing several hematologic cancers, particularly MDS and MPN, in patients with T2D.
This reduction in risk may be mediated by weight loss, the immunomodulatory properties of GLP-1RAs, or both.
These associations appear to be independent of glycemic control, potentially through the reduction of proinflammatory cytokines implicated in hematopoiesis dysregulation and the development of MDS and MPN.
Metformin is suggested to have potential cancer protective effects, which could account for the equivocal findings for non-MDS/MPN cancers in our analysis.
Nonetheless, our analysis suggests that GLP-1RAs represent a promising novel strategy for reducing cancer risk.
Study limitations include reliance on encounter codes, residual confounding by indication, limited adjustment for multiple testing and sensitivity analysis, lack of age stratification, and dose-response relationships.
Further prospective studies are needed to explore the biological pathways of GLP-1RAs in cancer prevention.”
“Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists”
Authors: Omer Ashruf, Jasmin Hundal, Ali Mushtaq, David Kaelber, Faiz Anwer, Abhay Singh.
More posts featuring James Crowley.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023